- Home
- CLLS vs SMTI Comparison
CLLS vs SMTI Comparison
Compare CLLS & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SMTI
- Stock Information
- Founded
- CLLS 1999
- SMTI 1982
- Country
- CLLS France
- SMTI United States
- Employees
- CLLS N/A
- SMTI N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SMTI Medical/Dental Instruments
- Sector
- CLLS Health Care
- SMTI Health Care
- Exchange
- CLLS Nasdaq
- SMTI Nasdaq
- Market Cap
- CLLS 240.2M
- SMTI 288.2M
- IPO Year
- CLLS 2007
- SMTI N/A
- Fundamental
- Price
- CLLS $1.57
- SMTI $33.01
- Analyst Decision
- CLLS Buy
- SMTI Buy
- Analyst Count
- CLLS 3
- SMTI 1
- Target Price
- CLLS $7.00
- SMTI $44.00
- AVG Volume (30 Days)
- CLLS 56.7K
- SMTI 36.2K
- Earning Date
- CLLS 11-04-2024
- SMTI 11-12-2024
- Dividend Yield
- CLLS N/A
- SMTI N/A
- EPS Growth
- CLLS N/A
- SMTI N/A
- EPS
- CLLS N/A
- SMTI N/A
- Revenue
- CLLS $36,042,000.00
- SMTI $78,056,873.00
- Revenue This Year
- CLLS $271.02
- SMTI $29.95
- Revenue Next Year
- CLLS $33.48
- SMTI $19.68
- P/E Ratio
- CLLS N/A
- SMTI N/A
- Revenue Growth
- CLLS 46.96
- SMTI 24.66
- 52 Week Low
- CLLS $1.53
- SMTI $26.00
- 52 Week High
- CLLS $3.55
- SMTI $43.25
- Technical
- Relative Strength Index (RSI)
- CLLS 27.91
- SMTI 34.95
- Support Level
- CLLS $1.85
- SMTI $31.13
- Resistance Level
- CLLS $2.09
- SMTI $34.22
- Average True Range (ATR)
- CLLS 0.09
- SMTI 1.80
- MACD
- CLLS -0.04
- SMTI -0.63
- Stochastic Oscillator
- CLLS 0.00
- SMTI 12.98
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.